Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

NCT00588146 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Schering-Plough discontinued supplying study drug.

Conditions

Anemia
Liver Disease
Hypoxemia

Interventions

DRUG: Pegylated Interferon Alpha2b
OTHER: Standard care

Sponsor

Mayo Clinic

Collaborators

[object Object]
[object Object]
[object Object]